Molecular dynamics simulations of amyloid fibrils: An in silico approach

Acta Biochimica et Biophysica Sinica

Volumn 45, Issue 6, 2013, Pages 503-508

  Ye, Wei ^a   Wang, Wei ^a   Jiang, Cheng ^a   Yu, Qingfen ^a   Chen, Haifeng ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI CENTER FOR BIOINFORMATION TECHNOLOGY   (China)

Author keywords

Amyloid fibrils; MD Simulation; Prion; Protein aggregation

Indexed keywords

AMYLOID;

ALZHEIMER DISEASE; AMYLOID FIBRILS; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; HUMAN; MD SIMULATION; METABOLISM; MOLECULAR DYNAMICS; PRION; PRION DISEASE; PROTEIN AGGREGATION; REVIEW;

AMYLOID FIBRILS; MD SIMULATION; PRION; PROTEIN AGGREGATION;

ALZHEIMER DISEASE; AMYLOID; ANIMALS; COMPUTER SIMULATION; HUMANS; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; PRION DISEASES;

EID: 84879222581     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmt026     Document Type: Review

References (73)

1. Aguzzi A, Sigurdson C and Heikenwaelder M. Molecular mechanisms of prion pathogenesis. Annu Rev Pathol 2008, 3: 11-40.
2. Collinge J. Prion diseases of humans and animals: their causes and molecular basis. Annu Rev Neurosci 2001, 24: 519-550.
3. Hardy J and Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297: 353-356.
4. Hebda JA and Miranker AD. The interplay of catalysis and toxicity by amyloid intermediates on lipid bilayers: insights from type II diabetes. Annu Rev Biophys 2009, 38: 125-152.
5. Auluck PK, Caraveo G and Lindquist S. a-Synuclein: membrane interactions and toxicity in Parkinson's disease. Annu Rev Cell Dev Biol 2010, 26: 211-233.
6. Chouard T. Structural biology: breaking the protein rules. Nature 2011, 471: 151-153.
7. Wright PE and Dyson HJ. Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm. J Mol Biol 1999, 293: 321-331.
8. Chiti F and Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 2006, 75: 333-366.
9. Gregersen N, Bross P, Vang S and Christensen JH. Protein misfolding and human disease. Annu Rev Genomics Hum Genet 2006, 7: 103-124.
10. Aguzzi A, Baumann F and Bremer J. The prion's elusive reason for being. Annu Rev Neurosci 2008, 31: 439-477.
11. Williamson RA, Peretz D, Smorodinsky N, Bastidas R, Serban H, Mehlhorn I and DeArmond SJ, et al. Circumventing tolerance to generate autologous monoclonal antibodies to the prion protein. Proc Natl Acad Sci USA 1996, 93: 7279-7282.
12. Makin OS, Atkins E, Sikorski P, Johansson J and Serpell LC. Molecular basis for amyloid fibril formation and stability. Proc Natl Acad Sci USA 2005, 102: 315-320.
13. Makin OS and Serpell LC. Structures for amyloid fibrils. FEBS J 2005, 272: 5950-5961.
14. Ma J and Lindquist S. Conversion of PrP to a self-perpetuating PrPSc-like conformation in the cytosol. Science 2002, 298: 1785-1788.
15. Petkova AT, Ishii Y, Balbach JJ, Antzutkin ON, Leapman RD, Delaglio F and Tycko R. A structural model for Alzheimer's beta-amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci USA 2002, 99: 16742-16747.
16. Nelson R, Sawaya MR, Balbirnie M, Madsen AO, Riekel C, Grothe R and Eisenberg D. Structure of the cross-beta spine of amyloid-like fibrils. Nature 2005, 435: 773-778.
17. Toyama BH and Weissman JS. Amyloid structure: conformational diversity and consequences. Annu Rev Biochem 2011, 80: 557-585.
18. Dunker AK, Silman I, Uversky VN and Sussman JL. Function and structure of inherently disordered proteins. Curr Opin Struct Biol 2008, 18: 756-764.
19. Hansson T, Oostenbrink C and van Gunsteren W. Molecular dynamics simulations. Curr Opin Struct Biol 2002, 12: 190-196.
20. Scheraga HA, Khalili M and Liwo A. Protein-folding dynamics: overview of molecular simulation techniques. Annu Rev Phys Chem 2007, 58: 57-83.
21. Ma B and Nussinov R. Simulations as analytical tools to understand protein aggregation and predict amyloid conformation. Curr Opin Chem Biol 2006, 10: 445-452.
22. Bixon M and Lifson S. Potential functions and conformations in cycloalkanes. Tetrahedron 1967, 23: 769-784.
23. Pearlman DA, Case DA, Caldwell JW, Ross WS, Cheatham TE, DeBolt S and Ferguson D, et al. AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules. Comput Phys Commun 1995, 91: 1-41.
24. Berendsen HJC, van der Spoel D and van Drunen R. GROMACS: a message-passing parallel molecular dynamics implementation. Comput Phys Commun 1995, 91: 43-56.
25. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S and Karplus M. CHARMM: a program for macromolecular energy, minimisation, and dynamics calculations. J Comput Chem 1983, 4: 187-217.
26. Jorgensen WL and Tirado-Rives J. The OPLS potential functions for proteins. Energy minimizations for crystals of cyclic peptides and crambin. J Am Chem Soc 1988, 110: 1657-1666.
27. Boehr DD and Wright PE. How do proteins interact? Science 2008, 320: 1429-1430.
28. Baker D. Metastable states and folding free energy barriers. Nat Struct Biol 1998, 5: 1021-1024.
29. Thomas WE, Vogel V and Sokurenko E. Biophysics of catch bonds. Annu Rev Biophys 2008, 37: 399-416.
30. Izrailev S, Stepaniants S and Schulten K. Applications of steered molecular dynamics to protein-ligand/membrane binding. Biophys J 1998, 74: A177-A177.
31. Izrailev S, Stepaniants S, Balsera M, Oono Y and Schulten K. Molecular dynamics study of unbinding of the avidin-biotin complex. Biophys J 1997, 72: 1568-1581.
32. Chen HF and Luo R. Binding induced folding in p53-MDM2 complex. J Am Chem Soc 2007, 129: 2930-2937.
33. Snow CD, Sorin EJ, Rhee YM and Pande VS. How well can simulation predict protein folding kinetics and thermodynamics? Annu Rev Biophys Biomol Struct 2005, 34: 43-69.
34. Vila-Vicosa D, Campos SR, Baptista AM and Machuqueiro M. Reversibility of prion misfolding: insights from constant-pH molecular dynamics simulations. J Phys Chem B 2012, 116: 8812-8821.
35. Gsponer J, Ferrara P and Caflisch A. Flexibility of the murine prion protein and its Asp178Asn mutant investigated by molecular dynamics simulations. J Mol Graph Model 2001, 20: 169-182.
36. Gu W, Wang TT, Zhu J, Shi YY and Liu HY. Molecular dynamics simulation of the unfolding of the human prion protein domain under low pH and high temperature conditions. Biophys Chem 2003, 104: 79-94.
37. Stahl N, Baldwin MA, Hecker R, Pan KM, Burlingame AL and Prusiner SB. Glycosylinositol phospholipid anchors of the scrapie and cellular prion proteins contain sialic acid. Biochemistry 1992, 31: 5043-5053.
38. Stahl N, Borchelt DR, Hsiao K and Prusiner SB. Scrapie prion protein contains a phosphatidylinositol glycolipid. Cell 1987, 51: 229-240.
39. Zuegg J and Gready JE. Molecular dynamics simulation of human prion protein including both N-linked oligosaccharides and the GPI anchor. Glycobiology 2000, 10: 959-974.
40. Bjorndahl TC, Zhou GP, Liu X, Perez-Pineiro R, Semenchenko V, Saleem F and Acharya S, et al. Detailed biophysical characterization of the acidinduced PrP(c) to PrP(beta) conversion process. Biochemistry 2011, 50: 1162-1173.
41. Campos SR, Machuqueiro M and Baptista AM. Constant-pH molecular dynamics simulations reveal a beta-rich form of the human prion protein. J Phys Chem B 2010, 114: 12692-12700.
42. Tompa P, Tusnady GE, Friedrich P and Simon I. The role of dimerization in prion replication. Biophys J 2002, 82: 1711-1718.
43. Ma B and Nussinov R. Molecular dynamics simulations of alanine rich beta-sheet oligomers: insight into amyloid formation. Protein Sci 2002, 11: 2335-2350.
44. Tang JL, Wu PJ, Wang SC and Lee CI. Insights into structural properties of denatured human prion 121-230 at melting temperature studied by replica exchange molecular dynamics. J Phys Chem B 2012, 116: 3305-3312.
45. Murphy RM. Peptide aggregation in neurodegenerative disease. Annu Rev Biomed Eng 2002, 4: 155-174.
46. Reinhard C, Hebert SS and De Strooper B. The amyloid-beta precursor protein: integrating structure with biological function. EMBO J 2005, 24: 3996-4006.
47. Rauk A. The chemistry of Alzheimer's disease. Chem Soc Rev 2009, 38: 2698-2715.
48. Lemkul JA and Bevan DR. Assessing the stability of Alzheimer's amyloid protofibrils using molecular dynamics. J Phys Chem B 2010, 114: 1652-1660.
49. Buchete NV, Tycko R and Hummer G. Molecular dynamics simulations of Alzheimer's b-amyloid protofilaments. J Mol Biol 2005, 353: 804-821.
50. Yan Y and Wang C. Protection mechanisms against Ab42 aggregation. Curr Alzheimer Res 2008, 5: 548-554.
51. Wang C. Solution NMR studies of Abeta monomer dynamics. Protein Pept Lett 2011, 18: 354-361.
52. Urbanc B, Cruz L, Yun S, Buldyrev SV, Bitan G, Teplow DB and Stanley HE. In silico study of amyloid beta-protein folding and oligomerization. Proc Natl Acad Sci USA 2004, 101: 17345-17350.
53. Xu Y, Shen J, Luo X, Zhu W, Chen K, Ma J and Jiang H. Conformational transition of amyloid beta-peptide. Proc Natl Acad Sci USA 2005, 102: 5403-5407.
54. Sawaya MR, Sambashivan S, Nelson R, Ivanova MI, Sievers SA, Apostol MI and Thompson MJ, et al. Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature 2007, 447: 453-457.
55. Wang J, Tan C, Chen HF and Luo R. All-atom computer simulations of amyloid fibrils disaggregation. Biophys J 2008, 95: 5037-5047.
56. Chen HF. Aggregation mechanism investigation of the GIFQINS cross-beta amyloid fibril. Comput Biol Chem 2009, 33: 41-45.
57. Chen Y, He YJ, Wu M, Yan G, Li Y, Zhang J and Chen HF. Insight into the stability of cross-beta amyloid fibril from molecular dynamics simulation. Biopolymers 2010, 93: 578-586.
58. Ye W, Chen Y, Wang W, Yu Q, Li Y, Zhang J and Chen HF. Insight into the stability of cross-beta amyloid fibril from VEALYL short peptide with molecular dynamics simulation. PLoS One 2012, 7: e36382.
59. Zanuy D and Nussinov R. The sequence dependence of fiber organization. A comparative molecular dynamics study of the islet amyloid polypeptide segments 22-27 and 22-29. J Mol Biol 2003, 329: 565-584.
60. de la Paz ML, de Mori GMS, Serrano L and Colombo G. Sequence dependence of amyloid fibril formation: insights from molecular dynamics simulations. J Mol Biol 2005, 349: 583-596.
61. Colombo G, Daidone I, Gazit E, Amadei A and Di Nola A. Molecular dynamics simulation of the aggregation of the core-recognition motif of the islet amyloid polypeptide in explicit water. Proteins 2005, 59: 519-527.
62. Dupuis NF, Wu C, Shea JE and Bowers MT. The amyloid formation mechanism in human IAPP: dimers have beta-strand monomer-monomer interfaces. J Am Chem Soc 2011, 133: 7240-7243.
63. Goldberg MS and Lansbury PT. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat Cell Biol 2000, 2: E115-E119.
64. Binolfi A, Quintanar L, Bertoncini CW, Griesinger C and Fernandez CO. Bioinorganic chemistry of copper coordination to alpha-synuclein: Relevance to Parkinson's disease. Coordination Chem Rev 2012, 256: 2188-2201.
65. Binolfi A, Rodriguez EE, Valensin D, D'Amelio N, Ippoliti E, Obal G and Duran R, et al. Bioinorganic chemistry of Parkinson's disease: structural determinants for the copper-mediated amyloid formation of alphasynuclein. Inorg Chem 2010, 49: 10668-10679.
66. Conway KA, Harper JD and Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med 1998, 4: 1318-1320.
67. Narhi L, Wood SJ, Steavenson S, Jiang Y, Wu GM, Anafi D and Kaufman SA, et al. Both familial Parkinson's disease mutations accelerate alphasynuclein aggregation. J Biol Chem 1999, 274: 9843-9846.
68. Hazy E, Bokor M, Kalmar L, Gelencser A, Kamasa P, Han KH and Tompa K, et al. Distinct hydration properties of wild-type and familial point mutant A53T of alpha-synuclein associated with Parkinson's disease. Biophys J 2011, 101: 2260-2266.
69. Chatterjee P and Sengupta N. Effect of the A30P mutation on the structural dynamics of micelle-bound alpha-synuclein released in water: a molecular dynamics study. Eur Biophys J 2012, 41: 483-489.
70. Lemkul JA and Bevan DR. The role of molecular simulations in the development of inhibitors of amyloid beta-peptide aggregation for the treatment of Alzheimer's disease. ACS Chem Neurosci 2012, 3: 845-856.
71. Tell V, Mahmoud KA, Wichapong K, Schaechtele C, Totzke F, Sippl W and Hilgeroth A. Novel aspects in structure-activity relationships of profiled 1-aza-9-oxafluorenes as inhibitors of Alzheimer's diseaserelevant kinases cdk1, cdk5 and gsk3 beta. MedChemComm 2012, 3: 1413-1418.
72. Li J, Liu R, Lam KS, Jin LW and Duan Y. Alzheimer's disease drug candidates stabilize A-beta protein native structure by interacting with the hydrophobic core. Biophys J 2011, 100: 1076-1082.
73. Urbanc B, Betnel M, Cruz L, Li H, Fradinger EA, Monien BH and Bitan G. Structural basis for Abeta1-42 toxicity inhibition by Ab C-terminal fragments: discrete molecular dynamics study. J Mol Biol 2011, 410: 316-328.